Letter to the editor: Aspirin use and the risk of hepatocellular carcinoma
- PMID: 35844049
- DOI: 10.1002/hep.32674
Letter to the editor: Aspirin use and the risk of hepatocellular carcinoma
Comment on
-
Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis.Hepatology. 2022 Aug;76(2):492-501. doi: 10.1002/hep.32380. Epub 2022 Mar 17. Hepatology. 2022. PMID: 35100447
References
-
- Jang H, Lee YB, Moon H, Chung JW, Nam JY, Cho EJ, et al. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology. 2022;76:492–501.
-
- Liao KF, Kuo YH, Lai SW. The risk of hepatocellular carcinoma and aspirin use. Pharmacol Res. 2020;159:104982.
-
- Targownik LE, Suissa S. Understanding and avoiding immortal‐time bias in gastrointestinal observational research. Am J Gastroenterol. 2015;110:1647–50.
-
- Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16:241–9.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
